DOES TRANSRECTAL ULTRASONOGRAPHY-GUIDED BIOPSY OF THE PROSTATE LEAD TO POSSIBLE FURTHER METASTASIS VIA CIRCULATING TUMOR CELLS?
Open Access
- 1 January 2019
- journal article
- research article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 49 (6) , 1701-1706
Abstract
Background/aim: We evaluate whether transrectal ultrasonography (rRUS)-guided prostate biopsy might lead to spillage of tumor cells into peripheral blood as a result of disruption of the epithelial barrier and ultimately result in metastasis. Materials and methods: Eighty-eight patients underwent 'FRUS-guided prostate needle biopsy due to prostate-specific antigen (PSA) increase or abnormal digital rectal examination at the Samsun Research and Training Hospital (Samsun, Turkey) between April 2016 and September 2018. Approximately 10 mL of whole blood was collected from patients before, 1 week after, and 1 month after biopsy. Samples were analyzed for CD117 positivity and prostate-specific membrane antigen (PSMA) levels using flow cytometry. Patients with pathologically determined prostate cancer and without CD117 positivity before biopsy were included in the study. The study group thus consisted of 55 patients. Results: Subjects' PSA levels ranged from 2.3 to 40.0 ng/mL (median: 7.9 ng/mL), and their Gleason score was a median of 7 (range: 5-9). PSMA levels ranged between 9.3 ng/mL and 118.5 ng/mL and CD117 antigen levels between 0 and 5. We detected no CD117-positive cells in blood samples collected 7 days or 1 month after biopsy. Conclusion: We detected no circulating tumor cells in the peripheral circulation following biopsy. Prostate needle biopsy seems to be a safe method in terms of spillage of tumor cells into blood circulation as a possible cause of further metastasis.Keywords
This publication has 15 references indexed in Scilit:
- Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate CancerCancer Discovery, 2012
- Circulating Tumor Cells as Biomarkers in Prostate CancerClinical Cancer Research, 2011
- Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future ChallengesCurrent Treatment Options in Oncology, 2010
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Circulating Tumor Cells in Peripheral Blood Samples From Patients With Increased Serum Prostate Specific Antigen: Initial Results in Early Prostate CancerJournal of Urology, 2008
- Overview of prostate-specific membrane antigen.2004
- Detection of carcinoma cells in the blood of breast cancer patientsThe American Journal of Surgery, 2000
- Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinomaCancer, 1998
- Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.1991
- Steel locus defines new multipotent growth factorCell, 1990